HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Jan. 18, 2006--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) has under development a new proprietary treatment of E. coli O157:H7, a potentially deadly form of a common bacteria that has proven to be a major public health threat to food and water supplies world-wide. In December, 18 children in Oregon became ill from drinking contaminated milk. Other recent outbreaks of deadly E. coli O157:H7 contamination have occurred in Wales, Ireland, France, Canada and the United States from a variety of sources, including ground beef, lettuce, bean sprouts, milk, water supplies and petting zoos. In the U.S. alone, E. coli O157 contamination causes an estimated 73,480 illnesses a year, with young children being particularly at risk for developing highly serious medical complications, and has led in the recall of over a million pounds of frozen ground beef in 2005.